Your browser doesn't support javascript.
loading
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
MacCumber, Mathew W; Wykoff, Charles C; Karcher, Helene; Adiguzel, Eser; Sinha, Samriddhi Buxy; Vishwakarma, Saloni; LaPrise, Andrew; Igwe, Franklin; Freitas, Rita; Ip, Michael S; Zarbin, Marco A.
Affiliation
  • MacCumber MW; Department of Ophthalmology, Rush University Medical Center and Illinois Retina Associates, Chicago, Illinois. Electronic address: mmaccumber@illinoisretina.com.
  • Wykoff CC; Retinal Consultants of Texas, Houston, Texas.
  • Karcher H; Novartis Pharma AG, Basel, Switzerland.
  • Adiguzel E; Novartis Pharmaceuticals Corp., East Hanover, New Jersey.
  • Sinha SB; Sandoz, a Novartis Division, Basel, Switzerland.
  • Vishwakarma S; Verana Health, Inc., San Francisco, California.
  • LaPrise A; Verana Health, Inc., San Francisco, California.
  • Igwe F; Novartis Pharma AG, Basel, Switzerland.
  • Freitas R; Novartis Farma-Produtos Farmacêuticos S.A., Porto Salvo, Portugal.
  • Ip MS; Doheny Eye Institute, University of California, Los Angeles, Los Angeles, California.
  • Zarbin MA; Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey.
Ophthalmology ; 130(8): 795-803, 2023 08.
Article in En | MEDLINE | ID: mdl-36990322
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Angiogenesis Inhibitors / Wet Macular Degeneration Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Angiogenesis Inhibitors / Wet Macular Degeneration Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article